Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus–1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The well-understood integration preferences of HIV-1 for active transcription units72 and MLV for promoter/enhancer regions73–75 are in large part dictated via specific interactions of the respective IN proteins with chromatin-bound host factors.”
From Structure and function of retroviral integrase (2022) · cites this paper as [73]
In the citing paper
“Multiple studies now indicate that gammaretroviral vectors such as the vectors used in the two SCID-X1 trials preferentially integrate into the 5′ end of genes, near the transcription start sites[47].”
From Finding the needle in the hay stack: Hematopoietic stem cells in Fanconi anemia (2009) · cites this paper as [47]
In the citing paper
“Finally, the preferred sequences of the genome for integration are different from the γ-RVV, with LVV preferentially integrating in genes and introns away for transcriptional start sites preferred by γ-RVV.20”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [20]
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Sustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
CpG islands as gene markers in the human genome
Larsen, F., Gundersen, G., Lopez, R., & Prydz, H. (1992) · Genomics · doi:10.1016/0888-7543(92)90024-m · Cited by 922
Pryciak, P. M., & Varmus, H. E. (1992) · Cell · doi:10.1016/0092-8674(92)90289-o · Cited by 273
Introducing RefSeq and LocusLink: curated human genome resources at the NCBI
Pruitt, K. D., Katz, K. S., Sicotte, H., & Maglott, D. R. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01882-x · Cited by 241
Check, E. (2002) · Nature · doi:10.1038/420116a · Cited by 238
Pruss, D., Bushman, F. D., & Wolffe, A. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5913 · Cited by 236
Transcriptionally active genome regions are preferred targets for retrovirus integration
Scherdin, U., Rhodes, K., & Breindl, M. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.907-912.1990 · Cited by 210
Research works printed but not linked: 2
- National Center for Biotechnology Information Reference Sequence Project (RefSeq) www.ncbi.nlm.nih.gov/RefSeq/.
- The database is available online at www.ncbi.nlm.nih.gov/geo/.
Cited by
Items 901–1,000 of 1,000
Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A
Zakas, P. M., Spencer, H. T., & Doering, C. B. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-003 · Cited by 8
“g-retroviral vectors integrate into chromosomal sites that are actively transcribed, including potential proto-oncogenes, resulting in aberrant transcription patterns and expression [50-54].”
de Freitas, M. C. C., Fontes, A. M., Fernandes, A. D. C., Picanço‐Castro, V., Russo, E. M. D. S., & Covas, D. T. (2014) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2014.03.002 · Cited by 9
Feldman, S. A., Xu, H., Black, M. A., Park, T. S., Robbins, P. F., Kochenderfer, J. N., Morgan, R. A., & Rosenberg, S. A. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2014.071 · Cited by 9
“However, the risk of insertional transformation is not completely abrogated by the use of these vectors (Wu et al., 2003; Modlich et al., 2009).”
Background(2007) · Wiley eBooks · doi:10.1002/9780470184585 · Cited by 8
Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans
Izotova, N., Rivat, C., Baricordi, C., Blanco, E., Pellin, D., Watt, E., Gkazi, S. A., Adams, S. P., Gilmour, K. C., Xu‐Bayford, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21834-9 · Cited by 8
Applications of DNA integrating elements: Facing the bias bully
de Jong, J., Wessels, L. F. A., van Lohuizen, M., de Ridder, J., & Akhtar, W. (2014) · Mobile Genetic Elements · doi:10.4161/2159256x.2014.992694 · Cited by 11
Sissolak, G., Abayomi, E. A., & Jacobs, P. (2007) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2007.04.010 · Cited by 8
“This process can arise randomly but recently found to occur within the transcriptional unit as opposed to downstream or upstream in any particular gene leading to activation all deactivation of genes that modulate cell cycle or cause apoptosis and thus candidates for promoting malignant transformation [18,19].”
BackgroundKirilov, M., Chai, M., van der Hoeven, F., Kloz, U., Schmid, W., & Schütz, G. (2007) · Transgenic Research · doi:10.1007/s11248-007-9119-6 · Cited by 9
“Recent evidence showed that murine leukemia virus (MLV) and HIV-based vectors integrate preferentially into highly expressed genes (Mitchell et al. 2004; Wu et al. 2003).”
BackgroundAdoptive T-cell therapy for B-cell malignancies
Hudecek, M., Anderson, L. D., Nishida, T., & Riddell, S. R. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.47 · Cited by 8
“Both RV and LV preferentially integrate into transcriptionally active genes, and entail a risk of insertional mutagenesis and transformation of modified T cells, although LVs are considered to be less genotoxic [99,100].”
BackgroundThe evolution of gene therapy in X-linked severe combined immunodeficiency
Rans, T. S., & England, R. W. (2009) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60504-2 · Cited by 8
Gene Therapy Studies in a Canine Model of X-Linked Severe Combined Immunodeficiency
Felsburg, P. J., Ravin, S. S. D., Malech, H. L., Sorrentino, B. P., Burtner, C. R., & Kiem, H. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.004 · Cited by 8
Genotoxicity Assay for Gene Therapy Vectors in Tumor Prone Cdkn2a−/− Mice
Montini, E., & Cesana, D. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00009-0 · Cited by 8
Adult T-cell Leukemia/Lymphoma
Watanabe, T., & Fukushima, T. (2017) · Springer eBooks · doi:10.1007/978-4-431-56523-9 · Cited by 8
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C. F., Kustikova, O. S., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-190 · Cited by 8
Construction of retroviral vectors with enhanced efficiency of transgene expression
Hahm, S. H., Yi, Y., Lee, D. K., Noh, M. J., Yun, L., Hwang, S., & Lee, K. H. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.05.014 · Cited by 8
“Although it has been generally accepted that retroviral incorporation into the host genome is a completely random process, recent experimental evidence suggests that retroviral integration favors sites of active gene expression (Schroder et al., 2002; Wu et al., 2003).”
BackgroundA high throughput method for genome-wide analysis of retroviral integration
Mantovani, J., Holic, N., Martinez, K., Danos, O., & Perea, J. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl716 · Cited by 8
“In our hands as much as 90% of obtained clones have the expected structure compared to 60% published by Burgess (8) who used LM-PCR.”
MethodResultGiordano, F. A., Fehse, B., Hotz‐Wagenblatt, A., Jonnakuty, S., del Val, C., Appelt, J.-U., Nagy, K. Z., Kuehlcke, K., Naundorf, S., Zander, A., et al. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705424 · Cited by 8
Engineering Baculo- and Lentiviral Vectors for Enhanced and Targeted Gene Delivery
Kaikkonen, M. U. (2008) · Cited by 8
Improved functionality and potency of next generation BinMLV viral vectors toward safer gene therapy
Looveren, D. V., Giacomazzi, G., Thiry, I., Sampaolesi, M., & Gijsbers, R. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.003 · Cited by 8
Häuser, H. (2014) · Cell engineering · doi:10.1007/978-3-319-10320-4_1 · Cited by 7
Gene Therapy Model of X-linked Severe Combined Immunodeficiency Using a Modified Foamy Virus Vector
Horino, S., Uchiyama, T., So, T., Nagashima, H., Sun, S., Sato, M., Asao, A., Haji, Y., Sasahara, Y., Candotti, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071594 · Cited by 7
“To determine the vector-integration sites, linker-mediated PCR was performed on genomic DNA isolated from cc-transduced ED40515(2) cells as previously described [13,25].”
MethodResultAlternative Splicing Caused by Lentiviral Integration in the Human Genome
Moiani, A., & Mavilio, F. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00008-9 · Cited by 7
Kohio, H. P., Ajoge, H. O., Coleman, M. D., Ndashimye, E., Gibson, R. M., Arts, E. J., & Barr, S. D. (2023) · Viruses · doi:10.3390/v15020465 · Cited by 7
Brief Histories of Retroviral Integration Research and Associated International Conferences
Grandgenett, D. P., & Engelman, A. (2024) · Viruses · doi:10.3390/v16040604 · Cited by 8
“Similar to the known integration-targeting biases of HIV-1 and Mo-MLV, which highly prefer active genes and promoter regions, respectively [73,121], Tf1 integration occurred upstream of open reading frames.”
ResultHuang, W., Deng, Y., Dong, W., Yuan, W., Wan, Y., Mo, X., Li, Y., Wang, Z., Wang, Y., Ocorr, K. A., et al. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0168-1 · Cited by 7
“The 50 upstream and 30 downstream genomic sequences flanking the Tol2 were amplified and identified by linker-mediated PCR as described previously [13].”
MethodSelf-citationUchida, N., Hsieh, M. M., Platner, C., Saunthararajah, Y., & Tisdale, J. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104022 · Cited by 7
“Additionally, the lentiviral vectors have a tendency to be integrated into activated genes (in euchromatin), and transgene expression can be inhibited by DNA methylation in promoter regions [10,11,12,13].”
Field, A.-C., & Qasim, W. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.14 · Cited by 7
HIV-1 Integration into Chromatin: New Insights and Future Perspectives
Lesbats, P., Lavigne, M., & Parissi, V. (2011) · Future Virology · doi:10.2217/fvl.11.84 · Cited by 7
Genetic Barcodes Facilitate Competitive Clonal Analyses In Vivo
Aranyossy, T., Thielecke, L., Glauche, I., Fehse, B., & Cornils, K. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.124 · Cited by 7
“Human immunodeficiency virus type 1–derived lentiviral vectors show a preference for integrating into transcribed gene regions but have a decreased tendency for promotor regions.(5,6,13,14) To”
Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics
Guimarães-Young, A., Feddersen, C. R., & Dupuy, A. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00611 · Cited by 7
“Moreover, non-random integration patterns are commonly observed, with murine leukemia virus (MLV) exhibiting bias for transcription start sites (TSSs) of transcriptionally active genes (52).”
BackgroundRetrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines
Li, J., Wei, S., Cao, C., Chen, K., He, H., & Gao, G. (2019) · Electronic Journal of Biotechnology · doi:10.1016/j.ejbt.2019.07.002 · Cited by 7
“generate genetically stable, highly expressing cell lines [15,16].”
Nombela, I., Michiels, M., Looveren, D. V., Marcelis, L., Ashkar, S. E., Belle, S. V., Bruggemans, A., Tousseyn, T., Schwaller, J., Christ, F., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01478-22 · Cited by 7
“We show that MLV preferentially integrates into promoters and enhancers under in vivo conditions, which is in line with results reported previously by other groups using cell lines and primary cells (5, 6, 81).”
ResultGene Therapy for Melanoma: Progress and Perspectives
Bryan, E., & Costanzi-Strauss, E. (2013) · InTech eBooks · doi:10.5772/54936 · Cited by 9
“Though neither has a specific integration site, gammaretroviruses have a greater tendency to integrate near the transcriptional start sites of cellular genes than lentivirus [15].”
BackgroundTang, Y., & Swanstrom, R. (2007) · Virology · doi:10.1016/j.virol.2007.09.023 · Cited by 7
“In addition, HIV-1 tends to integrate within genes rather than in flanking regions as do the gammaretroviruses (Schroder et al., 2002; Wu et al., 2003), which would be more compatible with enhancement of expression of an undisrupted gene.”
BackgroundJakobsen, J. E., Li, J., Moldt, B., Kragh, P. M., Callesen, H., Hertz, J. M., Bolund, L., Jørgensen, A. L., Mikkelsen, J. G., & Nielsen, A. L. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0089-z · Cited by 7
In Vitro Murine Leukemia Retroviral Integration and Structure Fluctuation of Target DNA
Tsuruyama, T., Liu, W., & Yoshikawa, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031533 · Cited by 7
“Although integration events have long been considered to occur randomly within the host genome, several recent findings have shown that integration of MLV and HIV-1 occurs more frequently in actively transcribed genes [3], or in promoter regions [4].”
BackgroundWen, L., Liang, D. S., Wu, L. Q., Cai, F., Pan, Q., Long, Z., Dai, H. P., Xia, K., & Jia Hui, X. I. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.018 · Cited by 7
Possible Applications for Replicating Hiv-1 Vectors
Das, A. T., Jeeninga, R. E., & Berkhout, B. (2010) · HIV Therapy · doi:10.2217/hiv.10.20 · Cited by 7
Enhancing human regulatory T cells in vitro for cell therapy applications
Milward, K. F., Wood, K. J., & Hester, J. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.012 · Cited by 8
“In fact, strong evidence has been reported that viral integration occurs preferentially within permissive open chromatin conformations that are enriched at actively-transcribed genomic sites[115,116].”
BackgroundŠenigl, F., Miklík, D., Auxt, M., & Hejnar, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx889 · Cited by 9
“As a proof of concept, MLV or HIV1 integration can be redirected by hybrid targeting factors (5,16,17).”
BackgroundInfluentialGene therapy. The legacy of Wacław Szybalski
Dulak, J. (2021) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5805 · Cited by 9
“In 2012, EMA has registered Glybera, an AAV1 vector harboring the lipoprotein lipase (LPL) gene, for application in familial LPL-deficient patients (Ylä-Herttuala, 2012), a very rare disease characterized by acute pancreatitis.”
BackgroundSpirin, P., Vilgelm, A. E., & Prassolov, V. (2008) · Molecular Biology · doi:10.1134/s002689330805018x · Cited by 7
“For instance, γ-retrovirus MuLV is integrated mostly in the promoter gene regions close to the transcription start [64], threatening activation of cell genes, including oncogenes, from the strong enhancer/promoter regions located in the 3'-LTR of the provirus.”
BackgroundHai, M., Adler, R. L., Bauer, T. R., Tuschong, L. M., Gu, Y.-C., Wu, X., & Hickstein, D. D. (2008) · Gene Therapy · doi:10.1038/gt.2008.52 · Cited by 7
Self-citationRakotobe, D., Violot, S., Hong, S. S., Gouet, P., & Boulanger, P. A. (2008) · Virology Journal · doi:10.1186/1743-422x-5-32 · Cited by 7
“It was also consistent with the finding that HIV-1 preferentially integrates into transcriptionally active regions of the host genome [22-25].”
ResultYamada, K., Tsukahara, T., Yoshino, K., Kojima, K., Agawa, H., Yamashita, Y., Amano, Y., Hatta, M., Matsuzaki, Y., Kurotori, N., et al. (2009) · Retrovirology · doi:10.1186/1742-4690-6-79 · Cited by 7
“In a previous report, we found fewer hotspots in HeLa cells than in TPA-Mat cells [11,13].”
BackgroundLentivirus-Mediated RNA Interference Therapy for Human Immunodeficiency Virus Type 1 Infection
Morris, K. V., & Rossi, J. J. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-209 · Cited by 7
Combinatorial RNA‐based Therapies for HIV‐1
Morris, K. V., & Rossi, J. J. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch23 · Cited by 6
Hall, C. A., Kravitz, R. H., Johnson, K. F., Sanek, N. A., Maiti, P., Ziemba, K. R., Liu, J., Andreev, D. O., Chrostowski, V. L., Collins, I. J., et al. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28323 · Cited by 6
“It is based on the use of replication ‐ incompetent retroviral vectors (retrovectors) to actively insert the desired genes into or around the transcription start point of genes (Mitchell et al., 2004; Wu et al., 2003).”
Grund, N., Maier, P., Giordano, F. A., Appelt, J. U., Zucknick, M., Li, L., Wenz, F. K., Zeller, W. J., Früehauf, S., Allgayer, H., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.116 · Cited by 7
“10 kb around ( A ) transcription start sites (TSS), ( B ) CpG islands, ( C ) short interspersed nucleotide elements (SINEs), and ( D ) long inter-spersed nucleotide elements (LINEs) for integration sites of the lentiviral vector.”
InfluentialYannaki, E., Psatha, N., Παπαδοπούλου, Α., Athanasopoulos, T., Gravanis, A., Roubelakis, M. G., Tsirigotis, P. D., Anagnostopoulos, Α., Anagnou, N. P., & Vassilopoulos, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.196 · Cited by 6
“11 In contrast, the LVVs seem to prefer actively transcribed genes whereas FV vectors show no preference for transcribing genes and only a weak preference for TSS. 12,13 A final introductory note should be addressed to the HSC per se ; these cells have the unique potential of un-limited self-renewal…”
Viral oncogenesis of δ-retroviruses, HTLV-1 and BLV, and recent advances in its diagnosis
Hossain, M. B., Tan, B. J. Y., & Satou, Y. (2025) · Virology · doi:10.1016/j.virol.2025.110461 · Cited by 7
Hoang, T. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000885 · Cited by 6
Transposon–Host Cell Interactions in the Regulation of Sleeping Beauty Transposition
Walisko, O., Jursch, T., Izsvák, Z., & Ivics, Z. (2008) · Genome dynamics and stability · doi:10.1007/7050_2008_042 · Cited by 9
Transgene Site-Specific Integration: Problems and Solutions
Bire, S., & Rouleux‐Bonnin, F. (2012) · Topics in current genetics · doi:10.1007/978-94-007-4531-5_1 · Cited by 8
Rosenberg, N. E. (2010) · Springer eBooks · doi:10.1007/978-0-387-09581-3_1 · Cited by 6
“For example, gammaretroviruses tend to integrate near the promoter regions of transcriptionally active genes (Hematti et al., 2004; Wu et al., 2003), whereas lentiviruses tend to integrate into transcription units without a preference for introns or exons (Mitchell et al.”
si-RNA-Mediated Silencing of ADRBK1 Gene Attenuates Breast Cancer Cell Proliferation
Zhang, C., Chen, X., Li, Y., Himaya, S. W. A., Wu, J., Shi, X., Liu, X., & Kim, S. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1653 · Cited by 6
Self-citationApplying horizontal gene transfer phenomena to enhance non-viral gene therapy
Elmer, J. J., Christensen, M. D., & Rege, K. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.025 · Cited by 9
Gene Trapping Techniques and Current Progress
Li, Y., & Zhang, J. (2006) · Acta Genetica Sinica · doi:10.1016/s0379-4172(06)60039-5 · Cited by 7
Self-citationThe Use of Viral Vectors in Introducing Genes into Agricultural Animal Species
Modric, T., & Mergia, A. (2009) · Animal Biotechnology · doi:10.1080/10495390903196380 · Cited by 6
“Retroviral vectors generally integrate randomly into the host genome, with some hot spots or preferred regions of integration (81, 82).”
BackgroundProspective therapeutic approaches in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
Cabrera-Pérez, R., Torres‐Torronteras, J., Vila‐Julià, F., Ortega, F. J., Cámara, Y., Barquinero, J., & Martí, R. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1090307 · Cited by 8
“6 Gene therapy During the last decade, gene therapy has re-emerged as an alternative strategy to treat many diseases, due to a better understanding of the diseases and of the factors involved in past pitfalls associated with the use of retroviral vectors [94-97] and the current improvement in available vectors, which…”
BackgroundDiener, Y., Bosio, A., & Bissels, U. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.08.004 · Cited by 6
HIV-Derived Vectors for Gene Therapy Targeting Dendritic Cells
Rossetti, M. M., Cavarelli, M., Gregori, S., & Scarlatti, G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4433-6_9 · Cited by 6
Meza, N. W., Bustamante, O. Q., Puyet, A., Río, P., Navarro, S., Díez, A., Bueren, J. A., Bautista, J. M., & Segovia, J. C. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.052 · Cited by 8
“…which integrate along the entire length of transcriptional regions but not in these regions flanking the transcriptional start site (Schroder et al ., 2002; Wu et al ., 2003; Laufs et al ., 2006), suggests the development of new human immunodeficiency virus-based LTR self-inactivating vectors.”
Safety and efficacy in retrovirally modified haematopoietic cell therapy
Li, Z., Modlich, U., & Baum, C. (2004) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.05.009 · Cited by 9
Gene Mapping, Discovery, and Expression
Bina, M. (2006) · Humana Press eBooks · doi:10.1385/1597450979 · Cited by 7
Hepatic gene therapy using lentiviral vectors: Has safety been established?
Dismuke, D. J., & Samulski, J. R. (2013) · Hepatology · doi:10.1002/hep.26460 · Cited by 6
“Although c-RV has been demonstrated to prefer integration near transcription start sites, LV has been shown to integrate into active genes.(10,15,16) Because of this difference in integration and the relative stability of lentiviral genetic material, LV has been considered less likely to cause insertional mutagenesis…”
BackgroundGene Therapy to Induce Cellular Resistance to HIV‐1 Infection: Lessons from Clinical Trials
Giacca, M. (2008) · Advances in pharmacology · doi:10.1016/s1054-3589(07)56010-2 · Cited by 6
Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication
Jehad, M. A., Ali, L. M., Pillai, V. N., Prabhu, S. G., Mustafa, F., & Rizvi, T. A. (2026) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf066 · Cited by 5
Vectors for gene therapy: A place for DNA transposon
Chénais, B. (2013) · Open Journal of Genetics · doi:10.4236/ojgen.2013.32a1001 · Cited by 6
“Most of the integrating viral vectors have integration site preferences leading to an integration site bias that may explain some adverse effects such as gene silencing or activation of cancer-related genes [51-54].”
BackgroundTsuruyama, T., Nakai, T., Hiratsuka, T., Jin, G., Nakamura, T., & Yoshikawa, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013841 · Cited by 5
“. Following statistical analysis, they reported that integration preferentially occurred at transcriptionally active genes, and similar data on murine leukemia retroviral integration were reported”
Promises and Challenges in Hematopoietic Stem Cell Gene Therapy
Kohlscheen, S., Bonig, H. B., & Modlich, U. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.141 · Cited by 5
“Gammaretroviruses integrate preferentially into promoter regions up-stream of the transcription start site of genes and CpG rich regions, 40 while lentiviruses tend to integrate into coding regions downstream of the transcription start site and gene dense regions.”
Lee, E., Moon, S., Abu-Bonsrah, K. D., Kim, Y. K., Hwang, M. Y., Kim, Y. J., Kim, S., Hwang, N. S.-Y., Kim, S., & Kim, B. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.07.001 · Cited by 5
Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Romero, Z. G., Toscano, M. G., Unciti-Broceta, J. D., Molina, I. J., & Martín, F. (2009) · Current Gene Therapy · doi:10.2174/156652309788921080 · Cited by 5
“Several studies in cell lines and animal models have demonstrated that MLV-derived vectors integration favour transcriptionally active genes, CpG islands and transcription start sites (TSSs) [28-30].”
BackgroundEnhancing siRNA effects in T cells for adoptive immunotherapy
Morris, K. V., Castanotto, D., Al-Kadhimi, Z. S., Jensen, M. C., Rossi, J. J., & Cooper, L. J. N. (2005) · Hematology · doi:10.1080/10245330500233569 · Cited by 5
“Lentiviruses, unlike retroviruses such as MoMLV, tend to preferentially integrate downstream of active promoters within the active transcriptional unit, potentially limiting their overall oncogenicity [63].”
BackgroundMetais, J., Topp, S., Doty, R. T., Borate, B. R., Nguyen, A.-D., Wolfsberg, T. G., Abkowitz, J. L., & Dunbar, C. E. (2010) · Gene Therapy · doi:10.1038/gt.2010.24 · Cited by 6
Yamaguchi, T., Morikawa, A., & Miyoshi, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.085 · Cited by 5
Role of SV40 Integration Site at Chromosomal Interval 1q21.1 in Immortalized CRL2504 Cells
Liu, J., Kaur, G., Zhawar, V. K., Zimonjic, D. B., Popescu, N. C., Kandpal, R. P., & Athwal, R. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1003 · Cited by 5
“The altered expression of specific genes is illustrated by integration of hepatitis B virus into cyclin A gene (27), MLV into transcription start sites (28), HIV-1 into transcriptionally active genes (29), TBLV near c-myc locus (30), and ecotropic MLV into STAT5A gene (31).”
BackgroundKolokoltsova, O. A., Domina, A. M., Kolokoltsov, A. A., Davey, R. A., Weaver, S. C., & Watowich, S. J. (2008) · Virology · doi:10.1016/j.virol.2008.03.025 · Cited by 5
“Retroviral preference for distinctive regions within a gene, governed by the virus-specific preintegrational complex, has been previously documented (Wu et al., 2003; Wu, Luke, and Burgess, 2006).”
BackgroundBaliga, C. S., van Maanen, M., Chastain, M. A., & Sutton, R. E. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.021 · Cited by 5
Perspectivas da terapia gênica
Costanzi-Strauss, E., & Strauss, B. E. (2015) · Revista de Medicina · doi:10.11606/issn.1679-9836.v94i4p211-222 · Cited by 35
Nam, J.-S., Lee, J.-E., Lee, K.-H., Yang, Y., Kim, S.-H., Bae, G., Noh, H., & Lim, K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.001 · Cited by 5
“For example, the strong integration preference of MLV-based gammaretroviral vectors for genomic regions near TSSs can lead to uncontrolled growth of transduced human cells through upregulation of downstream oncogenes.(7,8) This oncogenic potential may limit the use of gammaretroviral vectors in clinical applications.”
BackgroundLo, M., Rival‐Gervier, S., Pasceri, P., & Ellis, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037130 · Cited by 5
The epigenetic regulation of autonomous replicons
Hagedorn, C., Lipps, H. J., & Rupprecht, S. (2010) · BioMolecular Concepts · doi:10.1515/bmc.2010.009 · Cited by 5
“Adeno-associated viruses (AAVs) are per se non-integrating but are able to integrate with low frequency into chromosome 19 (59, 60).”
BackgroundBertolotti, R. (2009) · Gene Therapy and Regulation · doi:10.1142/s1568558609000102 · Cited by 5
Soto, J., Peña, Á., Salcedo-Cifuentes, M., Domínguez, M. C., Sánchez, A., & García‐Vallejo, F. (2010) · Infectio · doi:10.1016/s0123-9392(10)70089-8 · Cited by 5
“El mecanismo que proponemos sería similar a lo reportado para el virus de la inmunodeficiencia de los simios y el de la inmunodeficiencia felina (35), pero diferente para la integración que ocurre en el virus de la leucemia de ratón (murine leukemia virus, VLM), el virus del sarcoma/leucosis aviar (avian sarcoma leuko…”
BackgroundGhani, K., Cottin, S. C., de Campos-Lima, P. O., Caron, M., & Caruso, M. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1351 · Cited by 5
“Indeed, MLV vectors have approximately 20–25% bias towards integrating within 5 kb of a transcription start site, and therefore, are statistically more prone to activate cellular protooncogenes [25,26].”
BackgroundLessons from Viral Latency in T Cells: Manipulating HIV-1 Transcription by Sirna
Suzuki, K., & Kelleher, A. D. (2010) · HIV Therapy · doi:10.2217/hiv.10.1 · Cited by 6
Chemoprotection by Transfer of Resistance Genes
Budak-Alpdoǧan, T., & Bertino, J. R. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_34 · Cited by 5
Risks of Insertional Mutagenesis by DNA Transposons in Cancer Gene Therapy
Hackett, P. B., Starr, T. K., & Cooper, L. J. N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00005-1 · Cited by 6
Martín-Hernández, J., Sørensen, A. B., & Pedersen, F. S. (2006) · Virology · doi:10.1016/j.virol.2006.05.024 · Cited by 5
“…the latter case, it has been shown that avian sarcoma-leukosis virus (ASLV), human immunodeficiency virus (HIV), and MLV show distinct target site preferences, with MLV showing an inclination to integrate near transcription start sites (Hematti et al., 2004; Mitchell et al., 2004; Wu et al., 2003).”
BackgroundDevelopment of a Synthetic Promoter for Macrophage Gene Therapy
He, W., Qiang, M., Ma, W., Valente, A. J., Quinones, M. P., Wang, W., Reddick, R. L., Xiao, Q., Ahuja, S. S., Clark, R. A., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.ft-240 · Cited by 5
Cellular Cofactors of HIV Integration
Thys, W., Bartholomeeusen, K., Debyser, Z., & Rijck, J. D. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch9 · Cited by 4
Picanço‐Castro, V., Bonamino, M., Ramos, R. N., Cunha, R., de Oliveira, T. G. M., & Rego, E. M. (2021) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2021.09.008 · Cited by 4
“Thus, presenting a risk of insertional mutagenesis and dysregulation of genes adjacent to the integration site(5) and local hotspots.(6) The development and use of non-integrative vectors, or ones that integrate at specific locations, is an important goal for CAR therapy.”
BackgroundThemis, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-873-3_16 · Cited by 4
Recent advances in developing molecular tools for targeted genome engineering of mammalian cells
Lim, K. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.1.165 · Cited by 4
“The retroviruses with the enzyme variants produced altered integration patterns without significant preference for TSS (55).”
BackgroundSuleman, S., Alhaque, S., Guo, A. Y., Zhang, H., Payne, A. M., Zahn, M., Fawaz, S., Khalifa, M. S., Jobling, S., Hay, D. C., et al. (2025) · Gene Therapy · doi:10.1038/s41434-025-00550-9 · Cited by 4
Wang, B., Zhang, X., & Zhao, Z. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.101 · Cited by 4
Yu-Lin, X. U. E., Xiao, A., Wen, L., Jia, Y., Gao, Y., Zhu, Z., Lin, S., & Zhang, B. (2010) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2010.00301 · Cited by 4
A Scalable Cell-Loading System for Non-Viral Gene Delivery and Other Applications
Fratantoni, J. C., Dzekunov, S. M., Wang, S., & Liu, L. L. (2004) · BioProcessing Journal · doi:10.12665/j36.fratantoni · Cited by 4
Severe Combined Immunodeficiencies
VILLA, A. M., Moshous, D., de Villartay, J., Notarangelo, L. D., & Candotti, F. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405546-9.00004-2 · Cited by 4
Metadata
- Authors
- Wu, X., Li, Y., Crise, B., & Burgess, S. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Burgess, Shawn M.
- Venue
- Science
- Published
- 2003-06-13
- Volume
- 300
- Issue
- 5626
- Pages
- 1749-1751
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1637867377
- Cited by
- 1,305
- References
- 18
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 18 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 24 · 2017: 39 · 2016: 43 · 2015: 49 · 2014: 65 · 2013: 51 · 2012: 83
- FWCI
- 57.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01co12400-79-0-22)
- National Cancer Institute (N01CO12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Chromosomal and Genetic Variations
- Keywords
- retroviral integration, transcription start sites, murine leukemia virus, HIV-1, human genome, gene therapy
- MeSH terms
- Child, Genetic Vectors, HeLa Cells, Humans, Leukemia, Leukemia Virus, Murine, Promoter Regions, Genetic, Transcription, Genetic, Tumor Cells, Cultured, Genetic Therapy, HIV-1, Gene Expression, Genome, Human, Virus Integration, CpG Islands, Oligonucleotide Array Sequence Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.